saving lives + healing:
We are fighting for legalized & affordable access to psychedelic therapy, reduced penalties, and evidence-based policy reform through education, advocacy & collaboration.
Nevada Coalition for Psychedelic Medicines expresses our extreme gratitude to Senator Rochelle Nguyen, Bruno Moya, and Dr. Dustin Hines for their advocacy at the NAMI Southern Nevada Annual Conference!
In the words of Senator Nguyen:
"Just wrapped up our panel at the 2023 NAMI Southern Nevada's Annual Education Conference. Presenting alongside Dr. Dustin Hines and Bruno Moya was a privilege. The conversational program was rich, and the insights about mental health and the future of psychedelics were truly transformative. Feeling grateful for this collaborative platform!”
Thank you to Cofounder & Director of NCPM, Bruno Moya, for your hard work, expertise and enduring dedication to raising awareness around mental health and the great potential for healing through psychedelic medicines.
Why is the issue of psychedelic drug policy reform critical?
Our state and country are facing a mental health crisis.
The COVID-19 pandemic has had a significant impact on mental health, leading to increased levels of anxiety, depression, and addiction.
Each day between 17 and 22 veterans end their lives, with a recent study tragically revealing that number may be as high as 40 per day.
Our nation continues to battle the opiate epidemic.
Current treatments are ineffective and failing. There is a growing body of evidence demonstrating the therapeutic benefits of psychedelics, particularly for treating mental health conditions such as depression, anxiety, PTSD, addiction, OCD, and eating disorders. Clinical trials are underway to explore the therapeutic potential for psychedelic medicines such as psilocybin (the active compound in magic mushrooms) in treating neurodegenerative diseases such as Alzheimer’s and Parkinson’s. This evidence suggests that these substances have the potential to help address some of the most pressing public health issues facing society today.
Currently, most psychedelics are still classified as Schedule I substances, meaning they are considered to have a high potential for abuse and no accepted medical use. Decades of research have now demonstrated that psychedelic medicines such as psilocybin hold great therapeutic value and carry little, if any, potential for abuse. This has led to calls for drug policy reform to re-evaluate the scheduling of psychedelics and to allow for greater access to these substances for healing. In addition, the safety profile for classic psychedelic compounds such as psilocybin is far superior to that of alcohol and tobacco.
Leading neuropsychopharmacologist David Nutt's harm scale is a widely cited ranking system that compares the harmfulness of various drugs based on a range of criteria, including physical harm, dependence, and social harm. According to this scale, alcohol and tobacco are ranked among the most harmful drugs, whereas psilocybin is ranked relatively low in terms of harm. Psilocybin has a relatively low risk of physical harm and a favorable safety profile when used responsibly with appropriate guidance.
Legislation in Nevada
Senate Bill 242 has been signed into law.
This is a historic moment for Nevada. Now the hard work begins as we embark on this next chapter. The bill, which establishes the Psychedelic Medicines Working Group, lays an important and critical foundation for introducing legislation next session on the path toward decriminalization and legalization for therapeutic use. SB242 is the first piece of legislation in the history of the state of Nevada to touch psychedelics since the passing of the Controlled Substances Act in 1970. We commend our legislators for their efforts to revise outdated drug policy so that our citizens may pursue these novel treatments for healing without fear of prosecution. Join us in building a network to support this effort.